Compare PDX & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDX | ESPR |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | NY | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.4M | 793.7M |
| IPO Year | N/A | 2013 |
| Metric | PDX | ESPR |
|---|---|---|
| Price | $20.07 | $3.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 113.8K | ★ 3.1M |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | ★ 86.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $332,314,000.00 |
| Revenue This Year | N/A | $27.35 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 185.66 |
| 52 Week Low | $18.47 | $0.73 |
| 52 Week High | $25.61 | $4.18 |
| Indicator | PDX | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 45.00 |
| Support Level | $19.91 | $3.16 |
| Resistance Level | $20.36 | $3.41 |
| Average True Range (ATR) | 0.19 | 0.15 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 49.06 | 12.64 |
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.